Evaluating the prevalence and prognostic value of certain lung cancer related biomarkers (expression, mutation, methylation, proteins) in samples from patients enrolled in observational biomarker and therapeutic clinical trials to establish a translational biomarker database. The resultant data are analyzed in the context of (1) known clinico-pathological variables, (2) clinical prognosis and outcome in lung cancer patients, and (3) additional disease-specific biomarkers that have been profiled by ALCMI’s academic collaborators and biopharmaceutical partners. The results of these studies will help to guide clinical study designs as well as inform physicians and patients of the genetics and biology of their particular tumors.